News | May 12, 2023
Gilead acquires XinThera to strengthen pipeline in oncology
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Wider reach for nutraceuticals portfolio in Europe, Turkey and Egypt
Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
The partnership will capitalize on the combined capabilities of the two organizations
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
Subscribe To Our Newsletter & Stay Updated
